Based on the aggregated intelligence of 150,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, pharmaceutical giant GlaxoSmithKline (NYSE: GSK) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Glaxo's business and see what CAPS investors are saying about the stock right now.

Glaxo facts

Headquarters (Founded)

Brentford, U.K. (1935)

Market Cap

$97 billion

Industry

Pharmaceuticals

Trailing-12-Month Revenue

$42.7 billion

Management

CEO Andrew Witty (since 2008)

CFO Julian Heslop (since 2005)

Return on Capital (Average, Past 3 Years)

24.2%

Cash/Debt

$11 billion / $26.2 billion

Dividend Yield

6.1%

Competitors

Novartis (NYSE: NVS)

Pfizer (NYSE: PFE)

sanofi-aventis (NYSE: SNY)

Other Highly Rated Pharmaceutical Stocks

Johnson & Johnson (NYSE: JNJ)

Merck (NYSE: MRK)

Bristol-Myers Squibb (NYSE: BMY)

Sources: Capital IQ (a division of Standard & Poor's), Yahoo! Finance, and Motley Fool CAPS.

On CAPS, 96.5% of the 459 All-Star members who have rated Glaxo believe the stock will outperform the S&P 500 going forward. These bulls include nrlbuild and mrindependent, both of whom are ranked in the top 6% of our community.

Less than two months ago, nrlbuild highlighted Glaxo as a rather healthy high-yielder (which is even higher today):

I like the 5% dividend in a retirement account. Big pipeline of late stage drugs. Global company based in UK, so some hedge against the dollar. Strong cash flow. Appear to better (more conservative) with picking proper acquisitions than Pfizer. Drug companies are not going away.

In a pitch from just four days ago, mrindependent tapped the company's recent legal troubles as an opportunity to pounce:

GlaxoSmithKline is currently available at a discount due to concerns about Avandia lawsuits. Current dividend yield is over 6% and the forward p/e is less than 10. The evidence against Glaxo is inconclusive at this point and the potential damages are unclear. In my opinion the stock has been punished too severely.

What do you think about Glaxo, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Pfizer is a Motley Fool Inside Value pick, Novartis is a Global Gains choice, and Johnson & Johnson is a selection of Income Investor. Motley Fool Options has recommended a buy calls position on Johnson & Johnson. The Fool owns shares of Glaxo. The Fool's disclosure policy always gets a perfect score.